Search

Your search keyword '"Chamuleau, Martine E.D."' showing total 175 results
Start Over Author "Chamuleau, Martine E.D." Search Limiters Available in Library Collection
175 results on '"Chamuleau, Martine E.D."'

1. Validation of an Artificial Intelligence–Based Prediction Model Using 5 External PET/CT Datasets of Diffuse Large B-Cell Lymphoma.

Author

Ferrández, Maria C., Golla, Sandeep S.V., Eertink, Jakoba J., Wiegers, Sanne E., Zwezerijnen, Gerben J.C., Heymans, Martijn W., Lugtenburg, Pieternella J., Kurch, Lars, Hüttmann, Andreas, Hanoun, Christine, Dührsen, Ulrich, Barrington, Sally F., Mikhaeel, N. George, Ceriani, Luca, Zucca, Emanuele, Czibor, Sándor, Györke, Tamás, Chamuleau, Martine E.D., Zijlstra, Josée M., and Boellaard, Ronald

Published
2024
Full Text
View/download PDF

3. Treatment and outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma:a contemporary, nationwide, population-based study in the Netherlands

Author

Pennings, Elise R.A., Durmaz, Müjde, Visser, Otto, Posthuma, Eduardus F.M., Issa, Djamila E., Chamuleau, Martine E.D., Lugtenburg, Pieternella J., Kersten, Marie José, Dinmohamed, Avinash G., Pennings, Elise R.A., Durmaz, Müjde, Visser, Otto, Posthuma, Eduardus F.M., Issa, Djamila E., Chamuleau, Martine E.D., Lugtenburg, Pieternella J., Kersten, Marie José, and Dinmohamed, Avinash G.

Published
2024

4. Distinct peripheral T-cell and NK-cell profiles in HGBL-MYC/BCL2 vs patients with DLBCL NOS

Author

de Jonge, A. Vera, Duetz, Carolien, Bruins, Wassilis S.C., Korst, Charlotte L.B.M., Rentenaar, Rosa, Cosovic, Meliha, Eken, Merve, Twickler, Inoka, Nijland, Marcel, van der Poel, Marjolein W.M., de Heer, Koen, Klerk, Clara P.W., Strobbe, Leonie, Oosterveld, Margriet, Boersma, Rinske, Koene, Harry R., Roemer, Margaretha G.M., van Werkhoven, Erik, Chamuleau, Martine E.D., Mutis, Tuna, de Jonge, A. Vera, Duetz, Carolien, Bruins, Wassilis S.C., Korst, Charlotte L.B.M., Rentenaar, Rosa, Cosovic, Meliha, Eken, Merve, Twickler, Inoka, Nijland, Marcel, van der Poel, Marjolein W.M., de Heer, Koen, Klerk, Clara P.W., Strobbe, Leonie, Oosterveld, Margriet, Boersma, Rinske, Koene, Harry R., Roemer, Margaretha G.M., van Werkhoven, Erik, Chamuleau, Martine E.D., and Mutis, Tuna

Abstract

Patients with high-grade B-cell lymphoma with MYC and BCL2 rearrangements (HGBL-MYC/BCL2) respond poorly to immunochemotherapy compared with patients with diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) without a MYC rearrangement. This suggests a negative impact of lymphoma-intrinsic MYC on the immune system. To investigate this, we compared circulating T cells and natural killer (NK) cells of patients with HGBL-MYC/BCL2 (n = 66), patients with DLBCL NOS (n = 53), and age-matched healthy donors (HDs; n = 16) by flow cytometry and performed proliferation, cytokine production, and cytotoxicity assays. Compared with HDs, both lymphoma subtypes displayed similar frequencies of CD8+ T cells but decreased CD4+ T cells. Regulatory T-cell (Treg) frequencies were reduced only in patients with DLBCL NOS. Activated (HLA-DR+/ CD38+) T cells, PD-1+CD4+ T cells, and PD-1+Tregs were increased in both lymphoma subtypes, but PD-1+CD8+ T cells were increased only in HGBL-MYC/BCL2. Patients with DLBCL NOS, but not patients with HGBL-MYC/BCL2, exhibited higher frequencies of senescent T cells than HDs. Functional assays showed no overt differences between both lymphoma groups and HDs. Deeper analyses revealed that PD-1+ T cells of patients with HGBL-MYC/BCL2 were exhausted with impaired cytokine production and degranulation. Patients with DLBCL NOS, but not patients with HGBL-MYC/BCL2, exhibited higher frequencies of NK cells expressing inhibiting receptor NKG2A. Both lymphoma subtypes exhibited lower TIM-3+– and DNAM-1+–expressing NK cells. Although NK cells of patients with HGBL-MYC/BCL2 showed less degranulation, they were not defective in cytotoxicity. In conclusion, our results demonstrate an increased exhaustion in circulating T cells of patients with HGBL-MYC/BCL2. Nonetheless, the overall intact peripheral T-cell and NK-cell f

Published
2024

5. Survival disparities between children and adolescents and young adults for the major subtypes of non-Hodgkin lymphoma in the Netherlands:a large population-based study

Author

Schulpen, Maya, Beishuizen, Auke, Chamuleau, Martine E.D., Dinmohamed, Avinash G., Meyer-Wentrup, Friederike A.G., Vormoor, H. Josef, van der Wagen, Lotte E., Minnema, Monique C., Loeffen, Jan L.C., Karim-Kos, Henrike E., Schulpen, Maya, Beishuizen, Auke, Chamuleau, Martine E.D., Dinmohamed, Avinash G., Meyer-Wentrup, Friederike A.G., Vormoor, H. Josef, van der Wagen, Lotte E., Minnema, Monique C., Loeffen, Jan L.C., and Karim-Kos, Henrike E.

Published
2024

6. Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study

Author

Saberi Hosnijeh, Fatemeh, van der Straten, Lina, Kater, Arnon P., van Oers, Marinus H.J., Posthuma, Ward F.M., Chamuleau, Martine E.D., Bellido, Mar, Doorduijn, Jeanette K., van Gelder, Michel, Hoogendoorn, Mels, de Boer, Fransien, te Raa, G. Doreen, Kerst, J. Martijn, Marijt, Erik W.A., Raymakers, Reinier A.P., Koene, Harry R., Schaafsma, Martijn R., Dobber, Johan A., Tonino, Sanne H., Kersting, Sabina S., Langerak, Anton W., and Levin, Mark-David

Published
2020
Full Text
View/download PDF

7. Deep and Durable Responses with Epcoritamab SC Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma: Data from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort

Author

Linton, Kim M, primary, Jurczak, Wojciech, additional, Lugtenburg, Pieternella J., additional, Gyan, Emmanuel, additional, Sureda, Anna, additional, Christensen, Jacob Haaber, additional, Hess, Brian, additional, Tilly, Herve, additional, Cordoba, Raul, additional, Lewis, David John, additional, Okada, Craig, additional, Hutchings, Martin, additional, Clausen, Michael Roost, additional, Vitolo, Umberto, additional, Cochrane, Tara, additional, Leppä, Sirpa, additional, Chamuleau, Martine E.D., additional, Conlon, Rebekah, additional, Favaro, Elena, additional, Favaro, Diana, additional, Altıntaş, Işıl, additional, Liu, Yan, additional, and Thieblemont, Catherine, additional

Published
2024
Full Text
View/download PDF

8. Baseline radiomics features and MYC rearrangement status predict progression in aggressive B-cell lymphoma

Author

Eertink, Jakoba Johanna, Zwezerijnen, Gerben J.C., Wiegers, Sanne E., Pieplenbosch, Simone, Chamuleau, Martine E.D., Lugtenburg, Pieternella J., de Jong, Daphne, Ylstra, Bauke, Mendeville, Matias, Dührsen, Ulrich, Hanoun, Christine, Hüttmann, Andreas, Richter, Julia, Klapper, Wolfram, Jauw, Yvonne W.S., Hoekstra, Otto S., de Vet, Henrica C.W., Boellaard, Ronald, Zijlstra, Josée M., Radiology and nuclear medicine, Hematology, CCA - Cancer Treatment and quality of life, CCA - Cancer biology and immunology, Pathology, AII - Cancer immunology, CCA - Imaging and biomarkers, Epidemiology and Data Science, APH - Methodology, Amsterdam Neuroscience - Brain Imaging, and AII - Infectious diseases

Subjects
Medizin, Hematology
Abstract

We investigated whether the outcome prediction of patients with aggressive B-cell lymphoma can be improved by combining clinical, molecular genotype, and radiomics features. MYC, BCL2, and BCL6 rearrangements were assessed using fluorescence in situ hybridization. Seventeen radiomics features were extracted from the baseline positron emission tomography–computed tomography of 323 patients, which included maximum standardized uptake value (SUVmax), SUVpeak, SUVmean, metabolic tumor volume (MTV), total lesion glycolysis, and 12 dissemination features pertaining to distance, differences in uptake and volume between lesions, respectively. Logistic regression with backward feature selection was used to predict progression after 2 years. The predictive value of (1) International Prognostic Index (IPI); (2) IPI plus MYC; (3) IPI, MYC, and MTV; (4) radiomics; and (5) MYC plus radiomics models were tested using the cross-validated area under the curve (CV-AUC) and positive predictive values (PPVs). IPI yielded a CV-AUC of 0.65 ± 0.07 with a PPV of 29.6%. The IPI plus MYC model yielded a CV-AUC of 0.68 ± 0.08. IPI, MYC, and MTV yielded a CV-AUC of 0.74 ± 0.08. The highest model performance of the radiomics model was observed for MTV combined with the maximum distance between the largest lesion and another lesion, the maximum difference in SUVpeak between 2 lesions, and the sum of distances between all lesions, yielding an improved CV-AUC of 0.77 ± 0.07. The same radiomics features were retained when adding MYC (CV-AUC, 0.77 ± 0.07). PPV was highest for the MYC plus radiomics model (50.0%) and increased by 20% compared with the IPI (29.6%). Adding radiomics features improved model performance and PPV and can, therefore, aid in identifying poor prognosis patients.

Published
2023

9. P1128: EVALUATION OF STANDARD OF CARE IN SECOND-LINE FOR PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN THE PRE-CAR-T ERA: A DUTCH POPULATION-BASED STUDY

Author

Pennings, Elise R.A., primary, Durmaz, Müjde, additional, Visser, Otto, additional, Posthuma, Eduardus F.M., additional, Issa, Djamila E., additional, Chamuleau, Martine E.D., additional, Spanjaart, Anne M., additional, van Meerten, Tom, additional, Mutsaers, Pim G.N.J., additional, Jak, Margot, additional, van Dorp, Suzanne, additional, Vermaat, Joost S.P., additional, van der Poel, Marjolein W.M., additional, Kuipers, Maria T., additional, Thielen, Frederick W., additional, Uyl-de Groot, Carin A., additional, Lugtenburg, Pieternella J., additional, José Kersten, Marie, additional, and Dinmohamed, Avinash G., additional

Published
2023
Full Text
View/download PDF

10. Baseline PET radiomics outperform the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma

Author

Eertink, Jakoba Johanna, primary, Zwezerijnen, Gerben JC, additional, Heymans, Martijn, additional, Pieplenbosch, Simone, additional, Wiegers, Sanne Elisabeth, additional, Dührsen, Ulrich, additional, Hüttmann, Andreas, additional, Kurch, Lars, additional, Hanoun, Christine, additional, Lugtenburg, Pieternella J., additional, Barrington, Sally, additional, Mikhaeel, N. George, additional, Ceriani, Luca, additional, Zucca, Emanuele, additional, Czibor, Sandor, additional, Györke, Tamás, additional, Chamuleau, Martine E.D., additional, Hoekstra, Otto S, additional, De Vet, Henrica CW, additional, Boellaard, Ronald, additional, and Zijlstra, Josée M., additional

Published
2023
Full Text
View/download PDF

11. No sex differential in relative survival among older patients with DLBCL treated with R-CHOP21:A population-based study

Author

Geerdes, Emma E., Durmaz, Möjde, Lugtenburg, Pieternella J., Chamuleau, Martine E.D., Visser, Otto, Issa, Djamila E., Brouwer, Rolf E., Posthuma, Eduardus F.M., Zijlstra, Josée M., Kersten, Marie José, Dinmohamed, Avinash G., Geerdes, Emma E., Durmaz, Möjde, Lugtenburg, Pieternella J., Chamuleau, Martine E.D., Visser, Otto, Issa, Djamila E., Brouwer, Rolf E., Posthuma, Eduardus F.M., Zijlstra, Josée M., Kersten, Marie José, and Dinmohamed, Avinash G.

Published
2023

12. Genomic profiling of post-transplant lymphoproliferative disorders using cell-free DNA

Author

Veltmaat, Nick, Zhong, Yujie, de Jesus, Filipe Montes, Tan, Geok Wee, Bult, Johanna A.A., Terpstra, Martijn M., Mutsaers, Pim G.N.J., Stevens, Wendy B.C., Mous, Rogier, Vermaat, Joost S.P., Chamuleau, Martine E.D., Noordzij, Walter, Verschuuren, Erik A.M., Kok, Klaas, Kluiver, Joost L., Diepstra, Arjan, Plattel, Wouter J., van den Berg, Anke, Nijland, Marcel, Veltmaat, Nick, Zhong, Yujie, de Jesus, Filipe Montes, Tan, Geok Wee, Bult, Johanna A.A., Terpstra, Martijn M., Mutsaers, Pim G.N.J., Stevens, Wendy B.C., Mous, Rogier, Vermaat, Joost S.P., Chamuleau, Martine E.D., Noordzij, Walter, Verschuuren, Erik A.M., Kok, Klaas, Kluiver, Joost L., Diepstra, Arjan, Plattel, Wouter J., van den Berg, Anke, and Nijland, Marcel

Abstract

Diagnosing post-transplant lymphoproliferative disorder (PTLD) is challenging and often requires invasive procedures. Analyses of cell-free DNA (cfDNA) isolated from plasma is minimally invasive and highly effective for genomic profiling of tumors. We studied the feasibility of using cfDNA to profile PTLD and explore its potential to serve as a screening tool. We included seventeen patients with monomorphic PTLD after solid organ transplantation in this multi-center observational cohort study. We used low-coverage whole genome sequencing (lcWGS) to detect copy number variations (CNVs) and targeted next-generation sequencing (NGS) to identify Epstein-Barr virus (EBV) DNA load and somatic single nucleotide variants (SNVs) in cfDNA from plasma. Seven out of seventeen (41%) patients had EBV-positive tumors, and 13/17 (76%) had stage IV disease. Nine out of seventeen (56%) patients showed CNVs in cfDNA, with more CNVs in EBV-negative cases. Recurrent gains were detected for 3q, 11q, and 18q. Recurrent losses were observed at 6q. The fraction of EBV reads in cfDNA from EBV-positive patients was 3-log higher compared to controls and EBV-negative patients. 289 SNVs were identified, with a median of 19 per sample. SNV burden correlated significantly with lactate dehydrogenase levels. Similar SNV burdens were observed in EBV-negative and EBV-positive PTLD. The most commonly mutated genes were TP53 and KMT2D (41%), followed by SPEN, TET2 (35%), and ARID1A, IGLL5, and PIM1 (29%), indicating DNA damage response, epigenetic regulation, and B-cell signaling/NFkB pathways as drivers of PTLD. Overall, CNVs were more prevalent in EBV-negative lymphoma, while no difference was observed in the number of SNVs. Our data indicated the potential of analyzing cfDNA as a tool for PTLD screening and response monitoring.

Published
2023

13. The Dutch CAR-T Tumorboard Experience:Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands

Author

Spanjaart, Anne M., Pennings, Elise R.A., Mutsaers, Pim G.N.J., van Dorp, Suzanne, Jak, Margot, van Doesum, Jaap A., de Boer, Janneke W., Niezink, Anne G.H., Kos, Milan, Vermaat, Joost S.P., Sijs-Szabo, Aniko, van der Poel, Marjolein W.M., Nijhof, Inger S., Kuipers, Maria T., Chamuleau, Martine E.D., Lugtenburg, Pieternella J., Doorduijn, Jeanette K., Serroukh, Yasmina I.M., Minnema, Monique C., van Meerten, Tom, Kersten, Marie José, Spanjaart, Anne M., Pennings, Elise R.A., Mutsaers, Pim G.N.J., van Dorp, Suzanne, Jak, Margot, van Doesum, Jaap A., de Boer, Janneke W., Niezink, Anne G.H., Kos, Milan, Vermaat, Joost S.P., Sijs-Szabo, Aniko, van der Poel, Marjolein W.M., Nijhof, Inger S., Kuipers, Maria T., Chamuleau, Martine E.D., Lugtenburg, Pieternella J., Doorduijn, Jeanette K., Serroukh, Yasmina I.M., Minnema, Monique C., van Meerten, Tom, and Kersten, Marie José

Abstract

The real-world results of chimeric antigen receptor T-cell (CAR-T) therapy for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) substantially differ across countries. In the Netherlands, the CAR-T tumorboard facilitates a unique nationwide infrastructure for referral, eligibility assessment and data collection. The aim of this study was to evaluate real-world outcomes of axicabtagene ciloleucel (axi-cel) in the Dutch population, including the thus-far underreported effects on health-related quality of life (HR-QoL). All patients with R/R LBCL after ≥2 lines of systemic therapy referred for axi-cel treatment between May 2020–May 2022 were included (N = 250). Of the 160 apheresed patients, 145 patients received an axi-cel infusion. The main reason for ineligibility was rapidly progressive disease. The outcomes are better or at least comparable to other studies (best overall response rate: 84% (complete response: 66%); 12-month progression-free-survival rate and overall survival rate: 48% and 62%, respectively). The 12-month NRM was 5%, mainly caused by infections. Clinically meaningful improvement in several HR-QoL domains was observed from Month 9 onwards. Expert-directed patient selection can support effective and sustainable application of CAR-T treatment. Matched comparisons between cohorts will help to understand the differences in outcomes across countries and select best practices. Despite the favorable results, for a considerable proportion of patients with R/R LBCL there still is an unmet medical need.

Published
2023

14. A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients

Author

de Jonge, A. Vera, van Werkhoven, Erik, Dinmohamed, Avinash G., Nijland, Marcel, Zwinderman, Aeilko H., Bossuyt, Patrick M., Veldhuis, Martine S., Rutten, Emma G.G.M., Mous, Rogier, Vermaat, Joost S.P., Sandberg, Yorick, de Jongh, Eva, Bilgin, Yavuz M., Boersma, Rinske, Koene, Harry, Kersten, Marie José, de Jong, Daphne, Chamuleau, Martine E.D., de Jonge, A. Vera, van Werkhoven, Erik, Dinmohamed, Avinash G., Nijland, Marcel, Zwinderman, Aeilko H., Bossuyt, Patrick M., Veldhuis, Martine S., Rutten, Emma G.G.M., Mous, Rogier, Vermaat, Joost S.P., Sandberg, Yorick, de Jongh, Eva, Bilgin, Yavuz M., Boersma, Rinske, Koene, Harry, Kersten, Marie José, de Jong, Daphne, and Chamuleau, Martine E.D.

Abstract

Patients with MYC rearranged (MYC-R) diffuse large B-cell lymphoma (DLBCL) have a poor prognosis. Previously, we demonstrated in a single-arm phase II trial (HOVON-130) that addition of lenalidomide to R-CHOP (R2CHOP) is well-tolerated and yields similar complete metabolic remission rates as more intensive chemotherapy regimens in literature. In parallel with this single-arm interventional trial, a prospective observational screening cohort (HOVON-900) was open in which we identified all newly diagnosed MYC-R DLBCL patients in the Netherlands. Eligible patients from the observational cohort that were not included in the interventional trial served as control group in the present risk-adjusted comparison. R2CHOP treated patients from the interventional trial (n = 77) were younger than patients in the R-CHOP control cohort (n = 56) (median age 63 versus 70 years, p = 0.018) and they were more likely to have a lower WHO performance score (p = 0.013). We adjusted for differences at baseline using 1:1 matching, multivariable analysis, and weighting using the propensity score to reduce treatment-selection bias. These analyses consistently showed improved outcome after R2CHOP with HRs of 0.53, 0.51, and 0.59, respectively, for OS, and 0.53, 0.59, and 0.60 for PFS. Thus, this non-randomized risk-adjusted comparison supports R2CHOP as an additional treatment option for MYC-R DLBCL patients. [Figure not available: see fulltext.]

Published
2023

15. A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients

Author

MS Hematologie, Cancer, Infection & Immunity, de Jonge, A. Vera, van Werkhoven, Erik, Dinmohamed, Avinash G., Nijland, Marcel, Zwinderman, Aeilko H., Bossuyt, Patrick M., Veldhuis, Martine S., Rutten, Emma G.G.M., Mous, Rogier, Vermaat, Joost S.P., Sandberg, Yorick, de Jongh, Eva, Bilgin, Yavuz M., Boersma, Rinske, Koene, Harry, Kersten, Marie José, de Jong, Daphne, Chamuleau, Martine E.D., MS Hematologie, Cancer, Infection & Immunity, de Jonge, A. Vera, van Werkhoven, Erik, Dinmohamed, Avinash G., Nijland, Marcel, Zwinderman, Aeilko H., Bossuyt, Patrick M., Veldhuis, Martine S., Rutten, Emma G.G.M., Mous, Rogier, Vermaat, Joost S.P., Sandberg, Yorick, de Jongh, Eva, Bilgin, Yavuz M., Boersma, Rinske, Koene, Harry, Kersten, Marie José, de Jong, Daphne, and Chamuleau, Martine E.D.

Published
2023

16. Genomic profiling of post-transplant lymphoproliferative disorders using cell-free DNA

Author

MS Hematologie, Cancer, Infection & Immunity, Veltmaat, Nick, Zhong, Yujie, de Jesus, Filipe Montes, Tan, Geok Wee, Bult, Johanna A.A., Terpstra, Martijn M., Mutsaers, Pim G.N.J., Stevens, Wendy B.C., Mous, Rogier, Vermaat, Joost S.P., Chamuleau, Martine E.D., Noordzij, Walter, Verschuuren, Erik A.M., Kok, Klaas, Kluiver, Joost L., Diepstra, Arjan, Plattel, Wouter J., van den Berg, Anke, Nijland, Marcel, MS Hematologie, Cancer, Infection & Immunity, Veltmaat, Nick, Zhong, Yujie, de Jesus, Filipe Montes, Tan, Geok Wee, Bult, Johanna A.A., Terpstra, Martijn M., Mutsaers, Pim G.N.J., Stevens, Wendy B.C., Mous, Rogier, Vermaat, Joost S.P., Chamuleau, Martine E.D., Noordzij, Walter, Verschuuren, Erik A.M., Kok, Klaas, Kluiver, Joost L., Diepstra, Arjan, Plattel, Wouter J., van den Berg, Anke, and Nijland, Marcel

Published
2023

18. Therapies and Outcomes for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Contemporary, Nationwide, Population-Based Study in the Netherlands

Author

Pennings, Elise R.A., primary, Durmaz, Müjde, additional, Visser, Otto, additional, Posthuma, Eduardus F.M., additional, Issa, Djamila E., additional, Chamuleau, Martine E.D., additional, Lugtenburg, Pieternella, additional, Kersten, Marie José, additional, and Dinmohamed, Avinash G., additional

Published
2022
Full Text
View/download PDF

19. Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial

Author

Kersten, Marie José, primary, Dreyling, Martin, additional, Linton, Kim M., additional, Chitu, Dana, additional, Tonino, Sanne, additional, Kap, Marcel, additional, Liu, Roberto D, additional, Chamuleau, Martine E.D., additional, Visser, Hein P.J., additional, De Jongh, Eva, additional, Marijt, Erik WAF, additional, Leijs, Maria B.L., additional, Bilgin, Yavuz M., additional, Dürig, Jan, additional, McKay, Pamela, additional, Snijders, Tjeerd J.F., additional, Pettitt, Andrew, additional, Minnema, Monique C., additional, Prange-Krex, Gabriele, additional, Cuijpers, Maria, additional, Böhmer, Lara H., additional, Tick, Lidwine W., additional, Florschütz, Axel, additional, Silbermann, Matthijs, additional, Fijnheer, Rob, additional, Beeker, Aart, additional, Tolboom, Nelleke, additional, Mitea, Cristina, additional, Arens, Anne IJ, additional, Zwezerijnen, Gerben JC, additional, Klapper, Wolfram, additional, Coupland, Sarah E., additional, de Jong, Daphne, additional, Doorduijn, Jeanette K., additional, and Zijlstra, Josée M., additional

Published
2022
Full Text
View/download PDF

20. Outcome of Transformed Marginal Zone Lymphoma: A Population Based Study

Author

Bult, Johanna A.A., primary, Huisman, Francien, additional, Zhong, Yujie, additional, Veltmaat, Nick, additional, Tonino, Sanne, additional, Vermaat, Joost S.P., additional, Chamuleau, Martine E.D., additional, Diepstra, Arjan, additional, Plattel, Wouter J., additional, Van Den Berg, Anke, additional, Brink, Mirian, additional, and Nijland, Marcel, additional

Published
2022
Full Text
View/download PDF

21. The Position of MYC Rearrangements in the Genomic Landscape of Diffuse Large B-Cell Lymphoma

Author

Van Dijk, Erik, primary, Janssen, Jurriaan, additional, Mendeville, Matias, additional, Los-De Vries, G. Tjitske, additional, Roemer, Margaretha GM, additional, Stathi, Phylicia, additional, Richter, Julia, additional, Kim, Yong Soo, additional, Klapper, Wolfram, additional, Dührsen, Ulrich, additional, Hüttmann, Andreas, additional, Lugtenburg, P. J, additional, Zijlstra, Josée M., additional, Kersten, Marie Jose, additional, de Jong, Daphne, additional, Chamuleau, Martine E.D., additional, and Ylstra, Bauke, additional

Published
2022
Full Text
View/download PDF

22. Immune Profiling of Double and Triple Hit High Grade B Cell Lymphoma Patients Treated with DA-EPOCH Reveals Activation of T Cells and Reduced T Cell Exhaustion

Author

de Jonge, A.Vera, primary, Duetz, Carolien, additional, Bruins, Wassilis S.C., additional, van Werkhoven, Erik D., additional, Nijland, Marcel, additional, Van Der Poel, Marjolein W.M., additional, de Heer, Koen, additional, Klerk, Clara P.W., additional, Sandberg, Yorick, additional, Fijnheer, Rob, additional, Mutseaers, Pim, additional, Issa, Djamila E., additional, Böhmer, Lara H., additional, Van Kampen, Roel J.W., additional, Visser, Otto J., additional, de Jong, Daphne, additional, Zijlstra, Josée M., additional, Mutis, Tuna, additional, and Chamuleau, Martine E.D., additional

Published
2022
Full Text
View/download PDF

23. Genomic Landscaping of Post-Transplant Lymphoproliferative Disorders Using Circulating Tumor DNA

Author

Veltmaat, Nick, primary, Tan, Geok Wee, additional, Bult, Johanna A.A., additional, Zhong, Yujie, additional, Plattel, Wouter J., additional, Mous, Rogier, additional, Mutsaers, Pim, additional, Stevens, Wendy B.C., additional, Vermaat, Joost S.P., additional, Chamuleau, Martine E.D., additional, Diepstra, Arjan, additional, Van Den Berg, Anke, additional, Montes De Jesus, Filipe, additional, and Nijland, Marcel, additional

Published
2022
Full Text
View/download PDF

24. Plasma Extracellular Vesicle-Associated microRNAs for Early Response Prediction in Patients with High-Grade B-Cell Lymphoma

Author

Wang, Steven, primary, Drees, Esther E.E., additional, Gómez-Martín, Cristina, additional, De Jonge, A., additional, van Eijndhoven, Monique, additional, Groenewegen, Nils, additional, Veldt-Verkuijlen, Sandra, additional, Nijland, Marcel, additional, Van Der Poel, Marjolein W.M., additional, Sandberg, Yorick, additional, van Rijn, Rozemarijn, additional, Mutsaers, Pim, additional, Vergote, Vibeke K.J., additional, Kersten, Marie José, additional, Bilgin, Yavuz M., additional, Stevens, Wendy B.C., additional, Durian, Marc, additional, Snijders, Tjeerd J.F., additional, de Jong, Daphne, additional, Zijlstra, Josée M., additional, Chamuleau, Martine E.D., additional, and Pegtel, Dirk Michiel, additional

Published
2022
Full Text
View/download PDF

25. Special Anatomical Subtypes of Diffuse Large B-Cell Lymphoma Have Distinct Tumor Microenvironments

Author

Noordenbos, Troy, primary, De Groot, Fleur A, additional, De Groen, Ruben A.L., additional, De Haan, Lorraine M., additional, Krog, Ricki T., additional, Sijs-Szabo, Aniko, additional, Griffioen, Marieke, additional, de Groot, Rosa, additional, Heemskerk, Mirjam H.M., additional, Ijsselsteijn, Marieke E., additional, Terpstra, Valeska, additional, Nijland, Marcel, additional, Mutseaers, Pim, additional, Chamuleau, Martine E.D., additional, Kersten, Marie Jose, additional, Diepstra, Arjan, additional, Bovée, Judith, additional, Jansen, Patty M., additional, De Miranda, Noel F.C.C., additional, and Vermaat, Joost S.P., additional

Published
2022
Full Text
View/download PDF

26. Harnessing Cell-Free DNA Biological Features for Early Treatment Response Prediction in High Grade B-Cell Lymphoma

Author

van der Pol, Ymke, primary, Wang, Steven, additional, Moldovan, Norbert, additional, de Jonge, A.Vera, additional, Drees, Esther E.E., additional, Roemer, Margaretha, additional, Ylstra, Bauke, additional, Nijland, Marcel, additional, Van Der Poel, Marjolein W.M., additional, de Heer, Koen, additional, Klerk, Clara, additional, van Rijn, Rozemarijn, additional, Fijnheer, Rob, additional, Vergote, Vibeke K.J., additional, Beeker, Aart, additional, Nieuwenhuizen, Laurens, additional, Mous, Rogier, additional, Vermaat, Joost S.P., additional, Pegtel, D. Michiel, additional, Chamuleau, Martine E.D., additional, and Mouliere, Florent, additional

Published
2022
Full Text
View/download PDF

27. External Validation Shows That Baseline PET Radiomics Outperform the IPI Risk Score for Prediction of Outcome in DLBCL

Author

Eertink, Jakoba J, primary, Zwezerijnen, Gerben JC, additional, Heymans, Martijn W, additional, Pieplenbosch, Simone, additional, Wiegers, Sanne E, additional, Dührsen, Ulrich, additional, Hüttmann, Andreas, additional, Kurch, Lars, additional, Hanoun, Christine, additional, Lugtenburg, Pieternella, additional, Barrington, Sally F, additional, Mikhaeel, George, additional, Ceriani, Luca, additional, Zucca, Emanuele, additional, Czibor, Sandor, additional, Györke, Tamás, additional, Chamuleau, Martine E.D., additional, Hoekstra, Otto S, additional, de Vet, Henrica C.W, additional, Boellaard, Ronald, additional, and Zijlstra, Josée M., additional

Published
2022
Full Text
View/download PDF

28. A Propensity Score-Adjusted Comparison of Lenalidomide + R-CHOP Versus R-CHOP for MYC-Rearranged DLBCL Patients

Author

de Jonge, A. Vera, primary, van Werkhoven, Erik D., additional, Dinmohamed, Avinash G., additional, Nijland, Marcel, additional, Zwinderman, Aeilko H., additional, Bossuyt, Patrick M., additional, Veldhuis, Martine S., additional, Rutten, Emma G.G.M., additional, Mous, Rogier, additional, Vermaat, Joost S.P., additional, Sandberg, Yorick, additional, de Jongh, Eva, additional, Bilgin, Yavuz M., additional, Boersma, Rinske, additional, Koene, Harry R., additional, Kersten, Marie Jose, additional, de Jong, Daphne, additional, and Chamuleau, Martine E.D., additional

Published
2022
Full Text
View/download PDF

29. Biological and Clinical Implications of Gene-Expression Profiling in Diffuse Large B-Cell Lymphoma:A Proposal for a Targeted BLYM-777 Consortium Panel as Part of a Multilayered Analytical Approach

Author

De Groot, Fleur A., De Groen, Ruben A.L., van den Berg, Anke, Jansen, Patty M., Lam, King H., Mutsaers, Pim G.N.J., Van Noesel, Carel J.M., Chamuleau, Martine E.D., Stevens, Wendy B.C., Plaça, Jessica R., Mous, Rogier, Kersten, Marie José, Van Der Poel, Marjolein M.W., Tousseyn, Thomas, Woei-A-jin, F. J.Sherida H., Diepstra, Arjan, Nijland, Marcel, Vermaat, Joost S.P., De Groot, Fleur A., De Groen, Ruben A.L., van den Berg, Anke, Jansen, Patty M., Lam, King H., Mutsaers, Pim G.N.J., Van Noesel, Carel J.M., Chamuleau, Martine E.D., Stevens, Wendy B.C., Plaça, Jessica R., Mous, Rogier, Kersten, Marie José, Van Der Poel, Marjolein M.W., Tousseyn, Thomas, Woei-A-jin, F. J.Sherida H., Diepstra, Arjan, Nijland, Marcel, and Vermaat, Joost S.P.

Abstract

Gene-expression profiling (GEP) is used to study the molecular biology of lymphomas. Here, advancing insights from GEP studies in diffuse large B-cell lymphoma (DLBCL) lymphomagenesis are discussed. GEP studies elucidated subtypes based on cell-of-origin principles and profoundly changed the biological understanding of DLBCL with clinical relevance. Studies integrating GEP and next-generation DNA sequencing defined different molecular subtypes of DLBCL entities originating at specific anatomical localizations. With the emergence of high-throughput technologies, the tumor microenvironment (TME) has been recognized as a critical component in DLBCL pathogenesis. TME studies have characterized so-called “lymphoma microenvironments" and “ecotypes”. Despite gained insights, unexplained chemo-refractoriness in DLBCL remains. To further elucidate the complex biology of DLBCL, we propose a novel targeted GEP consortium panel, called BLYM-777. This knowledge-based biology-driven panel includes probes for 777 genes, covering many aspects regarding B-cell lymphomagenesis (f.e., MYC signature, TME, immune surveillance and resistance to CAR T-cell therapy). Regarding lymphomagenesis, upcoming DLBCL studies need to incorporate genomic and transcriptomic approaches with proteomic methods and correlate these multi-omics data with patient characteristics of well-defined and homogeneous cohorts. This multilayered methodology potentially enhances diagnostic classification of DLBCL subtypes, prognostication, and the development of novel targeted therapeutic strategies. Simple Summary: This review summarizes gene-expression profiling insights into the background and origination of diffuse large B-cell lymphomas (DLBCL). To further unravel the molecular biology of these lymphomas, a consortium panel called BLYM-777 was designed including genes important for subtype classifications, genetic pathways, tumor-microenvironment, immune response and resistance to targeted therapies. This revi

Published
2022

30. Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage:a nationwide, population-based study in the Netherlands, 1989–2018

Author

Durmaz, Müjde, Visser, Otto, Posthuma, Eduardus F.M., Brouwer, Rolf E., Issa, Djamila E., de Jong, Daphne, Lam, King H., Blijlevens, Nicole M.A., Zijlstra, Josée M., Chamuleau, Martine E.D., Lugtenburg, Pieternella J., Kersten, Marie José, Dinmohamed, Avinash G., Durmaz, Müjde, Visser, Otto, Posthuma, Eduardus F.M., Brouwer, Rolf E., Issa, Djamila E., de Jong, Daphne, Lam, King H., Blijlevens, Nicole M.A., Zijlstra, Josée M., Chamuleau, Martine E.D., Lugtenburg, Pieternella J., Kersten, Marie José, and Dinmohamed, Avinash G.

Abstract

It is unclear whether survival in diffuse large B-cell lymphoma (DLBCL) continues to increase in an era where rituximab-containing chemotherapy reigns for almost two decades. Therefore, we evaluated trends in primary therapy and relative survival (RS) among Dutch DLBCL patients diagnosed between 1989 and 2018. Analyses were performed separately according to the stage I (N = 6952) and stage II–IV disease (N = 20,676), stratified by calendar period and age (18–64, 65–74, and ≥75 years). The use of chemotherapy ± radiotherapy increased over time across all age and stage groups. As of the mid-2000s, >95% of chemotherapy-treated patients received chemoimmunotherapy, irrespective of age and stage. Overall, RS increased significantly over time across all age groups, especially after 2003 when rituximab-containing chemotherapy had become the standard of care. However, RS increased less pronounced between 2003–2010 and 2011–2018 than between 1989–2002 and 2003–2010. These findings were congruent across all studied stage groups. Five-year RS across the three age groups during 2011–2018 was 96%, 84%, and 67% for stage I DLBCL and 75%, 60%, and 46% for stage II–IV DLBCL. Collectively, survival in DLBCL increased modestly beyond the initial introduction of rituximab, with apparent survival differences across age and stage that warrant novel treatment approaches.

Published
2022

31. R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma

Author

Al-Sarayfi, Diana, Meeuwes, Frederik O., Durmaz, Müjde, Issa, Djamila E., Brouwer, Rolf E., Beeker, Aart, van Rhenen, Anna, Mutsaers, Pim G.N.J., Böhmer, Lara H., van der Poel, Marjolein W.M., Te Boome, Liane, van Meerten, Tom, Chamuleau, Martine E.D., Zijlstra, Josée M., Brink, Mirian, Nijland, Marcel, Al-Sarayfi, Diana, Meeuwes, Frederik O., Durmaz, Müjde, Issa, Djamila E., Brouwer, Rolf E., Beeker, Aart, van Rhenen, Anna, Mutsaers, Pim G.N.J., Böhmer, Lara H., van der Poel, Marjolein W.M., Te Boome, Liane, van Meerten, Tom, Chamuleau, Martine E.D., Zijlstra, Josée M., Brink, Mirian, and Nijland, Marcel

Published
2022

32. Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenstrom's Macroglobulinemia:Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study

Author

Kersten, Marie José, Amaador, Karima, Minnema, Monique C., Vos, Josephine M.I., Nasserinejad, Kazem, Kap, Marcel, Kastritis, Efstathios, Gavriatopoulou, Maria, Kraan, Willem, Chamuleau, Martine E.D., Deeren, Dries, Tick, Lidwine W., Doorduijn, Jeanette K., Offner, Fritz, Böhmer, Lara H., Liu, Roberto D., Pals, Steven T., Dimopoulos, Meletios A., Kersten, Marie José, Amaador, Karima, Minnema, Monique C., Vos, Josephine M.I., Nasserinejad, Kazem, Kap, Marcel, Kastritis, Efstathios, Gavriatopoulou, Maria, Kraan, Willem, Chamuleau, Martine E.D., Deeren, Dries, Tick, Lidwine W., Doorduijn, Jeanette K., Offner, Fritz, Böhmer, Lara H., Liu, Roberto D., Pals, Steven T., and Dimopoulos, Meletios A.

Abstract

PURPOSE: Proteasome inhibitors are effective in Waldenström's macroglobulinemia (WM) but require parenteral administration and are associated with polyneuropathy. We investigated efficacy and toxicity of the less neurotoxic oral proteasome inhibitor ixazomib combined with rituximab, in patients with relapsed WM. METHODS: resultsWe conducted a multicenter phase I/II trial with ixazomib, rituximab, and dexamethasone (IRD). Induction consisted of eight cycles IRD wherein rituximab was started in cycle 3, followed by rituximab maintenance. Phase I showed feasibility of 4 mg ixazomib. Primary end point for phase II was overall response rate (ORR [≥ minimal response]) after induction. RESULTS: A total of 59 patients were enrolled (median age, 69 years; range, 46-91 years). Median number of prior treatments was 2 (range, 1-7); 70% had an intermediate or high WM-IPSS (International Prognostic Scoring System for WM) score. After eight cycles, ORR was 71% (42 out of 59) (14% very good partial response [PR], 37% PR, and 20% minor response). Depth of response improved until month 12 (best ORR methods85% [50 out of 59]: 15% very good PR, 46% PR, and 24% minor response). Median duration of response was 36 months. The average hematocrit level increased significantly (0.33-0.38 L/L) after induction (P < .001). After two cycles of ixazomib and dexamethasone, immunoglobulin M levels decreased significantly (median 3,700-2,700 mg/dL, P < .0001). Median time to first response was 4 months. Median progression-free survival and overall survival were not reached. After median follow-up of 24 months (range, 7.4-54.3 months), progression-free survival and overall survival were 56% and 88%, respectively. Toxicity included mostly grade 2 or 3 cytopenias, grade 1 or 2 neurotoxicity, and grade 2 or 3 infections. No infusion-related reactions or immunoglobulin M flare occurred with use of subcutaneous rituximab. Quality of life imp

Published
2022

33. R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma

Author

MS Hematologie, Cancer, Al-Sarayfi, Diana, Meeuwes, Frederik O., Durmaz, Müjde, Issa, Djamila E., Brouwer, Rolf E., Beeker, Aart, van Rhenen, Anna, Mutsaers, Pim G.N.J., Böhmer, Lara H., van der Poel, Marjolein W.M., te Boome, Liane, van Meerten, Tom, Chamuleau, Martine E.D., Zijlstra, Josée M., Brink, Mirian, Nijland, Marcel, MS Hematologie, Cancer, Al-Sarayfi, Diana, Meeuwes, Frederik O., Durmaz, Müjde, Issa, Djamila E., Brouwer, Rolf E., Beeker, Aart, van Rhenen, Anna, Mutsaers, Pim G.N.J., Böhmer, Lara H., van der Poel, Marjolein W.M., te Boome, Liane, van Meerten, Tom, Chamuleau, Martine E.D., Zijlstra, Josée M., Brink, Mirian, and Nijland, Marcel

Published
2022

35. Combining PET Radiomic Features with MYC Gene Rearrangement Results in High Prediction of Outcome in Diffuse Large B-Cell Lymphoma

Author

Eertink, Jakoba J, primary, Zwezerijnen, Gerben J.C, additional, Wiegers, Sanne E, additional, Chamuleau, Martine E.D, additional, Lugtenburg, Pieternella, additional, De Jong, Daphne, additional, Ylstra, Bauke, additional, Mendeville, Matias, additional, Dührsen, Ulrich, additional, Hüttmann, Andreas, additional, Schmitz, Christine, additional, Richter, Julia, additional, Klapper, Wolfram, additional, Hoekstra, Otto S, additional, de Vet, Henrica C.W, additional, Boellaard, Ronald, additional, and Zijlstra, Josée M, additional

Published
2021
Full Text
View/download PDF

36. A Phase 1/2, Open-Label, Multicenter Study of Isatuximab in Combination with Cemiplimab in Patients with Lymphoma

Author

Carlo-Stella, Carmelo, primary, Zinzani, Pier Luigi Luigi, additional, Sureda, Anna, additional, Araújo, Luís Francisco, additional, Casasnovas, Olivier, additional, Carpio, Cecilia, additional, Yeh, Su-Peng, additional, Bouabdallah, Krimo, additional, Cartron, Guillaume, additional, Kim, Won Seog, additional, Cordoba, Raul, additional, Koh, Youngil, additional, Re, Alessandro, additional, Alves, Daniela, additional, Chamuleau, Martine E.D, additional, Le Gouill, Steven, additional, Lopez-Guillermo, Armando, additional, Moreira, Maria Ilidia, additional, Van Der Poel, Marjolein W.M., additional, Abbadessa, Giovanni, additional, Meng, Robin, additional, Ji, Ran, additional, Lepine, Lucie, additional, Saleem, Rao, additional, and Ribrag, Vincent, additional

Published
2021
Full Text
View/download PDF

37. High Grade B Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements Treated with DA-EPOCH-R Induction and Nivolumab Consolidation Treatment: Interim Results of the HOVON-152 Phase II Trial

Author

de Jonge, A. Vera, primary, van Werkhoven, Erik D., additional, Nijland, Marcel, additional, de Heer, Koen, additional, Van Der Poel, Marjolein W.M., additional, Sandberg, Yorick, additional, Klerk, Clara, additional, Drees, Esther E.E., additional, Roemer, Margaretha GM, additional, de Jong, Daphne, additional, Pegtel, D. Michiel, additional, van der Holt, Bronno, additional, Mutis, Tuna, additional, Zijlstra, Josée M, additional, Kersten, Marie José, additional, and Chamuleau, Martine E.D, additional

Published
2021
Full Text
View/download PDF

38. O17-1 Subcutaneous (SC) epcoritamab induces complete responses across R/R B-cell NHL subtypes: Updated dose-escalation data

Author

Hutchings, Martin, primary, Mous, Rogier, additional, Clausen, Michael Roost, additional, Johnson, Peter, additional, Linton, Kim M., additional, Chamuleau, Martine E.D., additional, Lewis, David J., additional, Balari, Anna Sureda, additional, Cunningham, David, additional, Oliveri, Roberto S., additional, DeMarco, Dena, additional, Elliott, Brian, additional, Chen, Kuo-mei, additional, and Lugtenburg, Pieternella J., additional

Published
2021
Full Text
View/download PDF

39. Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma:a Dutch population-based study

Author

Brink, Mirian, Kahle, Xaver U., Vermaat, Joost S.P., Zijlstra, Josée M., Chamuleau, Martine E.D., Kersten, Marie José, Plattel, Wouter J., Durmaz, Mujde, Lugtenburg, Elly, Stevens, Wendy B.C., Mous, Rogier, de Vries, Elisabeth G.E., van der Poel, Marjolein W.M., Nannan Panday, Prashant V., Huls, Gerwin, van Meerten, Tom, Nijland, Marcel, Brink, Mirian, Kahle, Xaver U., Vermaat, Joost S.P., Zijlstra, Josée M., Chamuleau, Martine E.D., Kersten, Marie José, Plattel, Wouter J., Durmaz, Mujde, Lugtenburg, Elly, Stevens, Wendy B.C., Mous, Rogier, de Vries, Elisabeth G.E., van der Poel, Marjolein W.M., Nannan Panday, Prashant V., Huls, Gerwin, van Meerten, Tom, and Nijland, Marcel

Published
2021

40. DA-EPOCH-R for High Grade B-Cell Lymphoma Patients with MYC and BCL2 and/or BCL6 Rearrangements: Clinical Results of the Induction Phase of the HOVON-152 Trial

Author

de Jonge, A.Vera, Kersten, Marie José, van Werkhoven, Erik, van der Poel, Marjolein, de Heer, Koen, Klerk, Clara, Sandberg, Yorick, Van Rijn, Rozemarijn S, Fijnheer, Rob, Mutsaers, Pim, Vergote, Vibeke, Issa, Djamila, Beeker, Aart, Bilgin, Yavuz M., Böhmer, Lara H., Nieuwenhuizen, Laurens, Stevens, Wendy, van Kampen, Roel JW, Mous, Rogier, Durian, Marc, Snijders, Tjeerd, Vermaat, Joost S.P, Visser, Otto, Zijlstra, Josée M., Hofwegen, Henk, Zanders, Helma G.J.M., Fu, Liping P., De Jong, Daphne, Nijland, Marcel, and Chamuleau, Martine E.D.

Published
2023
Full Text
View/download PDF

41. No Discernable Dysfunction of Peripheral T-Cells and NK-Cells Despite Distinct Phenotypes in MYC Rearranged Versus Non Rearranged B-Cell Lymphoma Patients

Author

de Jonge, A. Vera, Duetz, Carolien, Bruins, Wassilis S.C, Korst, Charlotte L.B.M., Rentenaar, Rosa, Cosovic, Meliha, Eken, Merve, Twickler, Inoka, Nijland, Marcel, Van Der Poel, Marjolein, de Heer, Koen, Klerk, Clara, Strobbe, Leonie, Oosterveld, Margriet, Boersma, Rinske, Koene, Harry R., van Werkhoven, Erik, Chamuleau, Martine E.D., and Mutis, Tuna

Published
2023
Full Text
View/download PDF

42. Mitigating the Risk of Cytokine Release Syndrome (CRS): Preliminary Results from a DLBCL Cohort of Epcore NHL-1

Author

Vose, Julie M., Feldman, Tatyana, Chamuleau, Martine E.D., Kim, Won Seog, Lugtenburg, Pieternella, Kim, Tae Min, Costa, Pau Abrisqueta, Cheah, Chan Y., Glimelius, Ingrid Cecilia, Hess, Brian, Jurczak, Wojciech, Musuraca, Gerardo, Olszewski, Adam J., Dinh, Minh, Kilavuz, Nurgul, Wielgos-Bonvallet, Monica, Li, Tommy, Li, Zhu, Eskelund, Christian, and Farooq, Umar

Published
2023
Full Text
View/download PDF

43. Epcoritamab SC Monotherapy Leads to Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: First Data Disclosure from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort

Author

Linton, Kim, Jurczak, Wojciech, Lugtenburg, Pieternella, Gyan, Emmanuel, Sureda Balari, Anna Maria, Christensen, Jacob Haaber, Hess, Brian, Tilly, Hervé, Cordoba, Raul, Lewis, David, Okada, Craig, Hutchings, Martin, Clausen, Michael Roost, Vitolo, Umberto, Cochrane, Tara, Leppa, Sirpa, Chamuleau, Martine E.D., Conlon, Rebekah, Favaro, Elena, Gernhardt, Diana, Altintas, Isil, Liu, Yan, and Thieblemont, Catherine

Published
2023
Full Text
View/download PDF

44. Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus phaselenalidomide:II HOVON trial results of a multicenter

Author

Chamuleau, Martine E.D., Burggraaff, Coreline N., Nijland, Marcel, Bakunina, Katerina, Mous, Rogier, Lugtenburg, Pieternella J., Dierickx, Daan, van Imhoff, Gustaaf W., Vermaat, Joost S.P., Marijt, Eric A.F., Visser, Otto, Mandigers, Caroline, Bilgin, Yavuz M., Beeker, Aart, Durian, Mark F., van Rees, Bas P., Bohmer, Lara H., Tick, Lidwine W., Boersma, Rinske S., Snijders, Tjeerd J.F., Schouten, Harry C., Koene, Harry R., de Jongh, Eva, Hijmering, Nathalie, Diepstra, Arjan, van de Berg, Anke, Arens, Anne I.J., Huijbregts, Julia, Hoekstra, Otto, Zijlstra, Josee M., de Jong, Daphne, and Kersten, Marie José

Abstract

atients with MYC-rearrangement positive large B-cell lymphoma (MYC+ LBCL) have an inferior prognosis following standard first-line therapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) compared to patients without MYC rearrangement. Although intensive chemotherapy regimens yield higher remission rates, toxicity remains a concern. Lenalidomide is an oral immunomodulatory drug which downregulates MYC and its target genes thereby providing support using lenalidomide as additional therapeutic option for MYC+ LBCL. A phase II trial was conducted evaluating the efficacy of lenalidomide (15 mg day 1-14) in combination with R-CHOP (R2CHOP) in newly diagnosed MYC+ LBCL patients identified through a nationwide MYCFISH screening program. The primary endpoint was complete metabolic response (CMR) on centrally reviewed 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)-computer tomography (CT)-scan at end-of-treatment. Secondary endpoints were overall survival (OS), disease-free survival (DFS) and event-free survival (EFS). Eighty-two patients with stage II-IV MYC+ LBCL were treated with six cycles of R2CHOP. At end of treatment, 67% (95% Confidence interval [CI]: 58-75) of the patients reached CMR. With a median follow-up of 25.4 months, 2-year estimates for OS, DFS, EFS were 73% (95% CI: 62-82), 75% (95% CI: 63-84) and 63% change to: (95% CI: 52-73) respectively. In this prospective trial for newly diagnosed MYC+ LBCL patients, we found that administering R2CHOP was safe, and yields comparable CMR and survival rates as in studies applying more intensive chemotherapy regimens. Hence, these findings offer new prospects for MYC+ LBCL patients and warrant comparison in prospective randomized clinical trials. This trial was registered at www.clinicaltrialsregister.eu (#2014-002654-39).

Published
2020

45. Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy; results from the HOVON 109 study

Author

Hosnijeh, Fatemeh Saberi, van der Straten, Lina, Kater, Arnon P., van Oers, Marinus H.J., Posthuma, Ward F.M., Chamuleau, Martine E.D., Bellido, Mar, Doorduijn, Jeanette K., van Gelder, Michel, Hoogendoorn, Mels, de Boer, Fransien, Doreen te Raa, G., Kerst, J. Martijn, Marijt, Erik W.A., Raymakers, Reinier A.P., Koene, Harry R., Schaafsma, Martijn R., Dobber, Johan A., Tonino, Sanne H., Kersting, Sabina S., Langerak, Anton W., Levin, Mark-David, Hosnijeh, Fatemeh Saberi, van der Straten, Lina, Kater, Arnon P., van Oers, Marinus H.J., Posthuma, Ward F.M., Chamuleau, Martine E.D., Bellido, Mar, Doorduijn, Jeanette K., van Gelder, Michel, Hoogendoorn, Mels, de Boer, Fransien, Doreen te Raa, G., Kerst, J. Martijn, Marijt, Erik W.A., Raymakers, Reinier A.P., Koene, Harry R., Schaafsma, Martijn R., Dobber, Johan A., Tonino, Sanne H., Kersting, Sabina S., Langerak, Anton W., and Levin, Mark-David

Published
2020

46. Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter phase II HOVON trial

Author

Chamuleau, Martine E.D., Burggraaff, Coreline N., Nijland, Marcel, Bakunina, Katerina, Mous, Rogier, Lugtenburg, Pieternella J., Arens, A.I.J., Jong, Daphne de, Kersten, Marie Jose, Chamuleau, Martine E.D., Burggraaff, Coreline N., Nijland, Marcel, Bakunina, Katerina, Mous, Rogier, Lugtenburg, Pieternella J., Arens, A.I.J., Jong, Daphne de, and Kersten, Marie Jose

Abstract

Contains fulltext : 228586.pdf (publisher's version ) (Open Access)

Published
2020

47. Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy; results from the HOVON 109 study

Author

IRAS OH Epidemiology Chemical Agents, dIRAS RA-2, Hosnijeh, Fatemeh Saberi, van der Straten, Lina, Kater, Arnon P., van Oers, Marinus H.J., Posthuma, Ward F.M., Chamuleau, Martine E.D., Bellido, Mar, Doorduijn, Jeanette K., van Gelder, Michel, Hoogendoorn, Mels, de Boer, Fransien, Doreen te Raa, G., Kerst, J. Martijn, Marijt, Erik W.A., Raymakers, Reinier A.P., Koene, Harry R., Schaafsma, Martijn R., Dobber, Johan A., Tonino, Sanne H., Kersting, Sabina S., Langerak, Anton W., Levin, Mark-David, IRAS OH Epidemiology Chemical Agents, dIRAS RA-2, Hosnijeh, Fatemeh Saberi, van der Straten, Lina, Kater, Arnon P., van Oers, Marinus H.J., Posthuma, Ward F.M., Chamuleau, Martine E.D., Bellido, Mar, Doorduijn, Jeanette K., van Gelder, Michel, Hoogendoorn, Mels, de Boer, Fransien, Doreen te Raa, G., Kerst, J. Martijn, Marijt, Erik W.A., Raymakers, Reinier A.P., Koene, Harry R., Schaafsma, Martijn R., Dobber, Johan A., Tonino, Sanne H., Kersting, Sabina S., Langerak, Anton W., and Levin, Mark-David

Published
2020

48. Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter phase II HOVON trial: II HOVON trial results of a multicenter

Author

Stamceltransplantatieteam, MS Hematologie, Infection & Immunity, Cancer, Chamuleau, Martine E.D., Burggraaff, Coreline N., Nijland, Marcel, Bakunina, Katerina, Mous, Rogier, Lugtenburg, Pieternella J., Dierickx, Daan, van Imhoff, Gustaaf W., Vermaat, Joost S.P., Marijt, Eric A.F., Visser, Otto, Mandigers, Caroline, Bilgin, Yavuz M., Beeker, Aart, Durian, Mark F., van Rees, Bas P., Bohmer, Lara H., Tick, Lidwine W., Boersma, Rinske S., Snijders, Tjeerd J.F., Schouten, Harry C., Koene, Harry R., de Jongh, Eva, Hijmering, Nathalie, Diepstra, Arjan, van de Berg, Anke, Arens, Anne I.J., Huijbregts, Julia, Hoekstra, Otto, Zijlstra, Josee M., de Jong, Daphne, Kersten, Marie José, Stamceltransplantatieteam, MS Hematologie, Infection & Immunity, Cancer, Chamuleau, Martine E.D., Burggraaff, Coreline N., Nijland, Marcel, Bakunina, Katerina, Mous, Rogier, Lugtenburg, Pieternella J., Dierickx, Daan, van Imhoff, Gustaaf W., Vermaat, Joost S.P., Marijt, Eric A.F., Visser, Otto, Mandigers, Caroline, Bilgin, Yavuz M., Beeker, Aart, Durian, Mark F., van Rees, Bas P., Bohmer, Lara H., Tick, Lidwine W., Boersma, Rinske S., Snijders, Tjeerd J.F., Schouten, Harry C., Koene, Harry R., de Jongh, Eva, Hijmering, Nathalie, Diepstra, Arjan, van de Berg, Anke, Arens, Anne I.J., Huijbregts, Julia, Hoekstra, Otto, Zijlstra, Josee M., de Jong, Daphne, and Kersten, Marie José

Published
2020

49. Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study

Author

Stamceltransplantatieteam, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Saberi Hosnijeh, Fatemeh, van der Straten, Lina, Kater, Arnon P., van Oers, Marinus H.J., Posthuma, Ward F.M., Chamuleau, Martine E.D., Bellido, Mar, Doorduijn, Jeanette K., van Gelder, Michel, Hoogendoorn, Mels, de Boer, Fransien, te Raa, G. Doreen, Kerst, J. Martijn, Marijt, Erik W.A., Raymakers, Reinier A.P., Koene, Harry R., Schaafsma, Martijn R., Dobber, Johan A., Tonino, Sanne H., Kersting, Sabina S., Langerak, Anton W., Levin, Mark David, Stamceltransplantatieteam, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Saberi Hosnijeh, Fatemeh, van der Straten, Lina, Kater, Arnon P., van Oers, Marinus H.J., Posthuma, Ward F.M., Chamuleau, Martine E.D., Bellido, Mar, Doorduijn, Jeanette K., van Gelder, Michel, Hoogendoorn, Mels, de Boer, Fransien, te Raa, G. Doreen, Kerst, J. Martijn, Marijt, Erik W.A., Raymakers, Reinier A.P., Koene, Harry R., Schaafsma, Martijn R., Dobber, Johan A., Tonino, Sanne H., Kersting, Sabina S., Langerak, Anton W., and Levin, Mark David

Published
2020

50. Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data

Author

Hutchings, Martin, primary, Mous, Rogier, additional, Clausen, Michael Roost, additional, Johnson, Peter, additional, Linton, Kim M, additional, Chamuleau, Martine E.D., additional, Lewis, David John, additional, Sureda Balari, Anna, additional, Cunningham, David, additional, Oliveri, Roberto S, additional, DeMarco, Dena, additional, Elliott, Brian, additional, Chen, Kuo-mei, additional, and Lugtenburg, Pieternella J., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results